Compare AAME & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AAME | BEAT |
|---|---|---|
| Founded | 1968 | 2015 |
| Country | United States | United States |
| Employees | N/A | 16 |
| Industry | Life Insurance | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.7M | 44.8M |
| IPO Year | 1995 | N/A |
| Metric | AAME | BEAT |
|---|---|---|
| Price | $2.53 | $1.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.17 |
| AVG Volume (30 Days) | 6.2K | ★ 859.5K |
| Earning Date | 05-12-2026 | 03-12-2026 |
| Dividend Yield | ★ 0.84% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $188,227,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $260.78 |
| P/E Ratio | $10.86 | ★ N/A |
| Revenue Growth | ★ 0.77 | N/A |
| 52 Week Low | $1.26 | $0.54 |
| 52 Week High | $3.71 | $4.00 |
| Indicator | AAME | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 46.39 | 36.67 |
| Support Level | $2.54 | $0.91 |
| Resistance Level | $2.63 | $1.35 |
| Average True Range (ATR) | 0.15 | 0.09 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 32.69 | 8.24 |
Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.